Pharmaceutical Driven primarily by strong demand for engineered antibodies for treating a growing list of cancers, commercial protein drugs - a group that includes recombinant monoclonal antibodies, cytokines and related immune modulators, growth factors, enzymes and hormones - are forecast to increase at a 9.7% compound annual growth rate (CAGR) over the next four years, reaching a value of $103 billion by 2014, according to the latest estimates from Greystone Research Associates. 11 November 2010